STRATA Skin Sciences, Inc. (SSKN)
NASDAQ: SSKN · Real-Time Price · USD
1.350
-0.030 (-2.17%)
At close: Nov 19, 2025, 4:00 PM EST
1.354
+0.004 (0.30%)
After-hours: Nov 19, 2025, 6:50 PM EST
STRATA Skin Sciences Revenue
STRATA Skin Sciences had revenue of $6.93M in the quarter ending September 30, 2025, a decrease of -21.23%. This brings the company's revenue in the last twelve months to $30.98M, down -5.19% year-over-year. In the year 2024, STRATA Skin Sciences had annual revenue of $33.56M with 0.61% growth.
Revenue (ttm)
$30.98M
Revenue Growth
-5.19%
P/S Ratio
0.19
Revenue / Employee
$292,264
Employees
106
Market Cap
7.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.56M | 204.00K | 0.61% |
| Dec 31, 2023 | 33.36M | -2.80M | -7.75% |
| Dec 31, 2022 | 36.16M | 6.18M | 20.63% |
| Dec 31, 2021 | 29.98M | 6.89M | 29.83% |
| Dec 31, 2020 | 23.09M | -8.50M | -26.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SSKN News
- 6 days ago - STRATA Skin Sciences, Inc. (SSKN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion - GlobeNewsWire
- 14 days ago - STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update - GlobeNewsWire
- 5 weeks ago - Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides - GlobeNewsWire
- 6 weeks ago - Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences' XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis - GlobeNewsWire
- 7 weeks ago - STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis - GlobeNewsWire
- 2 months ago - New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences' Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach - GlobeNewsWire
- 2 months ago - STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering - GlobeNewsWire